Peer-reviewed veterinary case report
Immune cell markers in canine skin histiocytoma tumors
By Belluco, Sara et al.·Published in Veterinary pathology·2020·Université, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: FOXP3, CD208, and CD206 Expression in Canine Cutaneous Histiocytoma.
- Species:
- dog
Plain-English summary
A dog with a skin tumor called a cutaneous histiocytoma was studied to understand how the immune system might help it shrink on its own. Researchers looked at different markers in the tumor to see how immune cells were involved in this process. They found that certain immune cells were present in higher numbers as the tumor regressed, suggesting that the immune response plays a role in the tumor's natural decline. This study helps clarify how the immune system interacts with these types of tumors in dogs, but more research is needed to fully understand the process.
People also search for: dog skin tumor treatment · cutaneous histiocytoma in dogs · immune system and dog tumors
Abstract
Canine cutaneous histiocytoma (CCH) is a noninfectious tumor that spontaneously regresses. It is suggested that this regression is due to tumor cell maturation, which is responsible for CD8 lymphocyte activation and tumor cell destruction. Nevertheless, the possible role of the immune microenvironment in tumor regression has not been investigated to date. The aim of this study was to investigate the expression of CD208 and FoxP3 as markers of dendritic cells and regulatory T lymphocytes, respectively, and tumor cell expression of CD206 as a marker of Langerhans cell activation, and relate these parameters to the different phases of CCH and to intratumoral T cell infiltration. Formalin-fixed, paraffin-embedded samples from 31 CCH were evaluated. In each case, the mitotic count and regression phase were recorded. Within the tumor, a quantitative evaluation of immunolabeled CD208cells, FoxP3cells, and CD3lymphocytes was performed, as well as the CD206tumor cell location. Intratumoral CD208cells correlated with CD3lymphocytic infiltration. The possible role of dendritic cells in tumor regression was not confirmed since CD208 seemed to be a nonspecific marker for canine dendritic cells. FoxP3lymphocyte density was not correlated with any parameter. Neoplastic Langerhans cells presented progressive CD206 expression, from the bottom of the tumor to the epidermis, which correlated with the tumor regression phase and with intratumoral T lymphocyte infiltration. In conclusion, we confirmed a CD206 phenotype change in tumor cells in a spatial group-related pattern, supporting the hypothesis that tumoral Langerhans cells acquire a mature phenotype with tumor regression.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32783525/